KHK7580の第3相臨床試験

基本情報

NCT ID

NCT02549417

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

39

治験依頼者名

Kyowa Kirin Co., Ltd.

概要

This study is designed to evaluate efficacy and safety of KHK7580 orally administered once daily for 32 weeks for patients with secondary hyperparathyroidism receiving peritoneal dialysis. After 32-week treatment period, the subjects will receive KHK7580 in the 20-week extension period to evaluate long-term safety and efficacy.

対象疾患

介入

依頼者（Sponsor）